IN THE NAM OF GOD >

Dr.Maria Shrvani > Infectious Disease Specialist >

MUCORMYCOSIS AND COVID -19

MUCORMYCOSIS >

Mucormycosis, previously called zygomycosis, refers to several different diseases caused by infection with fungi belonging to the order Mucorales. Most mucormycosis infections are lifethreatening.

Risk factors such as diabetic ketoacidosis & neutropenia are present in most cases.

Successful mucormycosis treatment requires correction of the underlying risk factor(s), antifungal therapy (traditionally with a polyene), and aggressive surgery.

Etiology and Pathophysiology

• Risk factors:

- Diabetes mellitus \rightarrow especially ketoacidosis
- Patients with cancer, especially → neutropenic & receiving broad-spectrum antibiotics
- Patients with immunosuppressive agents→ steroids & TNF-alpha blockers
- Patients with hematologic cancer → CMV inf.
 & GVHD

Etiology and Pathophysiology • Prior receipt of voriconazole • Extreme malnutrition \rightarrow GI • Deferoxamine use (older iron chelators) • Trauma & contaminated medical supplies over wounds \rightarrow cutaneous mucormycosis.

Etiology and Pathophysiology


- Nonsterile tape & contaminated wooden splints with trauma/surgery
- Presence of a preexisting wound or IV line.
- Patients with burns
- No identifiable risk factors.

Pathophysiology

- Mucorales are ubiquitous fungi that are commonly found in soil and in decaying matter.
- Rhizopus can be found in moldy bread.
- The major route of infection → inhalation of conidia
- Other routes:
 - Ingestion
 - Traumatic inoculation

Pathophysiology


- fungal hyphae invade blood vessels, producing tissue infarction, necrosis, and thrombosis.
- When spores are deposited in:
 Nasal turbinates → rhinocerebral disease
 Lungs → pulmonary
 Ingested → GI disease
 Interrupted skin → cutaneous disease



History and Physical Examination

Rhinocerebral disease
Pulmonary disease
Cutaneous disease
Gastrointestinal
Disseminated disease
Central nervous system















Prognosis

- Prognosis and survival depend on early diagnosis and timely initiation of treatment.
- Mortality varies between 40%-80%, despite advances in treatment
- Mortality depends on the site of infection.

Prognosis

- Higher mortality of 80% → disseminated disease to CNS
- Rhino-orbital-cereberal→ mortality rate of 25% to 62%
- Rapid diagnosis, and early surgical debridement, lead to lower mortality



Diagnosis

Imaging



- Non-pigmented hyphae showing tissue invasion must be shown in tissue sections stained with haematoxylin-eosin ,periodic acid-Schiff stain or Grocott-Gomori's methenamine-silver stain or both.
- Histopathologically, Mucorales hyphae have a variable width of 6–16 $\mu m,$ but may be up to 25 $\mu m,$ and are non-septate or pauci-septate



COVID-19 and Mucormycosis

COVID-19 disease can be complicated by:

- Secondary bacterial infection
- Invasive fungal infection (COVID-19-associated pulmonary aspergillosis, Pneumocystosis, and mucormycosis)

Criteria for the clinical diagnosis of mucormycosis are still considered to be gold standard and include:

Black, necrotic turbinate's easily mistaken for dried, crusted Blood
Blood-tinged nasal discharge and facial pain, both on the same side

Criteria for the clinical diagnosis of mucormycosis are still considered to be gold standard and include:

- Soft peri-orbital or peri-nasal swelling with discoloration and induration
- Ptosis of the eyelid, proptosis of the eyeball and complete ophthalmoplegia & Multiple cranial nerve palsies unrelated to documented lesions

A number of triggers that may precipitate mucormycosis in people with COVID-19 in relation to corticosteroids:

- Presence of DM with or without DKA increases the risk of contracting mucormycosis and DM is often associated with an increased severity of COVID-19,
- Uncontrolled hyperglycemia and precipitation of DKA is often observed due to corticosteroid intake.
- Low pH due to acidosis is a fertile media for mucor spores to germinate.

 Low pH due to acidosis is a fertile media for mucor spores to germinate.

 Steroid use reduces the phagocytic activity of WBC (both first line and second line defense mechanism), causes impairment of bronchoalveolar macrophages migration, ingestion, and phagolysosome fusion, making a diabetic patient exceptionally vulnerable to mucormycosis.

 COVID-19 often causes endothelialitis, endothelial damage, thrombosis, lymphopenia, and reduction in CD4 and CD8 T-cell level and thus predisposes to secondary or opportunistic fungal infection, • Free available iron is an ideal resource for mucormycosis.

 Hyperglycemia causes glycosylation of transferrin & ferritin, & reduces iron binding allowing increased free iron. Increase in cytokines in patients with COVID-19 especially interleukin-6, increases free iron by increasing ferritin levels due to increased synthesis and decreased iron transport.

 Concomitant acidosis increases free iron by the same mechanism and additionally by reducing the ability of transferrin to chelate iron,

COVID-19 and Mucormycosis

- The most common clinical manifestation was rhino-orbital form.
- Case fatality at 12 weeks was 45.7% with no difference in mortality among COVID-19 and non-COVID-19 patients.
- Case reports describe patients who were diagnosed with rhinocerebral mucormycosis and COVID-19 simultaneously

 Patient who was diagnosed with GI mucormycosis five days after admission for COVID-19 treated with both steroids and tocilizumab COVID-19 has a predisposition to cause extensive lung damage, which promotes colonization and infection of invasive fungi of airway, sinuses, and lung.


 Alteration in T cell immunity, use of steroids, and broad-spectrum antibiotics are additional risk factors for acquiring invasive fungal infection. COVID-19 disrupts iron metabolism, resulting in high ferritin state and increasing intracellular iron, which causes tissue damage.

 This causes more iron to be released into the circulation, and it is this increase in free iron that is a risk factor for mucormycosis. Patients with diabetes and infected with SARS-CoV2 are at increased risk for mucormycosis

 A retrospective study conducted in India from Sep -Dec 2020, reported a 2.0 fold rise in 2020 compared to 2019 of COVID-19 mucormycosis One review of case reports of mucormycosis in patients with COVID-19 included 101 cases:

- 80 % had pre-existing diabetes mellitus
- 76 % received glucocorticoids
- The majority of cases were from India
 - 90 % of cases involved the nose and sinuses
- Overall mortality was 31 %

 Clinicians should be aware of the potential for rhinocerebral mucormycosis as a complication of COVID-19, especially in patients with underlying diabetes mellitus.



THANKS FOR ATTENTION >